Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02496143 · ClinicalTrials.gov registry record · Phase 1
A Safety and PK Study of EC-18 in Healthy Subjects
A Phase 1 study of Chemotherapy-induced Neutropenia, sponsored by Enzychem Lifesciences Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT02496143 is a Phase 1 study of Chemotherapy-induced Neutropenia that has completed, run by Enzychem Lifesciences Corporation. The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02496143, a Phase 1 study of Chemotherapy-induced Neutropenia, has completed, sponsored by Enzychem Lifesciences Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if EC-18 is safe and tolerable in healthy subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EC-18
Study Locations (1)
North Carolina
- Carolina Phase I Clinical Research - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-07 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02496143
The ClinicalTrials.gov registry entry for NCT02496143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enzychem Lifesciences Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chemotherapy-induced Neutropenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02496143 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02496143 about?
NCT02496143 is a clinical study titled "A Safety and PK Study of EC-18 in Healthy Subjects". The purpose of this study is to determine if EC-18 is safe and tolerable in healthy subjects.
What is the current status of trial NCT02496143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-07. Estimated completion is 2015-12.
What conditions does trial NCT02496143 study?
This clinical trial studies the following conditions: Chemotherapy-induced Neutropenia.
What interventions are being tested in trial NCT02496143?
The interventions under investigation include: Placebo (DRUG), EC-18 (DRUG).
Who is sponsoring clinical trial NCT02496143?
This trial is sponsored by Enzychem Lifesciences Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02496143 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Neutropenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.